Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion

Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. Some patients with HCC are diagnosed with macrovascular invasion (MVI), which is associated with a poorer prognosis. In Taiwan, sorafenib is the first-line therapy for patients with advanced HCC. However, the ef...

Full description

Bibliographic Details
Main Authors: Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Cheng-Yuan Peng
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Current Oncology
Subjects:
sorafenib
hepatocellular carcinoma
macrovascular invasion
post-operation
Online Access:https://www.mdpi.com/1718-7729/30/12/737

Internet

https://www.mdpi.com/1718-7729/30/12/737

Similar Items